Pulse Biosciences, Inc. PLSE
At closeNov 6, 2026, 7:18 PM EST
After hours · Nov 6, 7:18 PM ET
- YTD
- +288.13%
- 1 year
- +238.78%
- Market cap
- 3.80B
- Revenue (ttm)
- 1.49M
- EPS (ttm)
- -1.18
- Shares out
- 71.32M
- Forward P/E
- -45.55
- YTD return
- +288.13%
- 1-year return
- +238.78%
- Volume
- 428.50K
- Avg volume
- 510.96K
- Open
- 56.87
- Previous close
- 53.07
- Day's range
- 50.31 – 56.87
- 52-week range
- 12.66 – 57.06
- Price target
- 62.33 (+17.0%)
- Earnings date
- Feb 18, 2027
5D -0.84 (-1.56%)
Key statistics
- Enterprise value
- 3.72B
- PEG ratio
- 0.00
- Price / sales
- 2544.03
- Price / book
- 21.28
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 359.30%
- Free cash flow
- -46.42M
- Total cash
- 189.19M
- Total debt
- 6.36M
- Return on equity
- -60.61%
- Short % of float
- 14.09%
- 50-day average
- 51.45
- 200-day average
- 32.14
Analyst view
- Target (low)
- 55.00
- Target (mean)
- 62.33
- Target (high)
- 73.00
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 18, 2027
Expected Feb 18, 2027. Consensus EPS estimate -0.30.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 18, 2027 | Dec 30, 2026 | -0.35 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -0.3095 | -0.32 | -0.01 | -3.39% |
| Aug 6, 2026 | Jun 30, 2026 | -0.31 | -0.36 | -0.05 | -16.13% |
| May 4, 2026 | Mar 31, 2026 | -0.32 | -0.27 | +0.05 | +15.62% |
| Feb 19, 2026 | Dec 31, 2025 | -0.265 | -0.26 | +0.01 | +1.89% |
| Nov 5, 2025 | Sep 30, 2025 | -0.31 | -0.29 | +0.02 | +6.45% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Canaccord Genuity | main | Buy | Buy |
| Nov 6, 2026 | Needham | main | Buy | Buy |
| Oct 13, 2026 | Oppenheimer | main | Outperform | Outperform |
| Oct 6, 2026 | Canaccord Genuity | main | Buy | Buy |
| Sep 23, 2026 | BTIG | init | — | Buy |
| Sep 9, 2026 | Freedom Capital Markets | init | — | Buy |
About Pulse Biosciences, Inc.
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- pulsebiosciences.com
News
Canaccord Genuity Maintains Buy on Pulse Biosciences, Raises Price Target to $74 
Needham Maintains Buy on Pulse Biosciences, Raises Price Target to $64 
Pulse Biosciences Presents Six-Month Interim Results From PRECISE-BTN Thyroid Nodule Study, At 95th ATA Annual Meeting 
Pulse Biosciences, Inc. (PLSE) Q3 2026 Earnings Call Transcript 
Pulse Biosciences Q3 2026 Earnings Call Transcript - Pulse Biosciences Partners With Clayman Thyroid Center At Hospital For Endocrine Surgery In Tampa, Florida
Oppenheimer Maintains Outperform on Pulse Biosciences, Raises Price Target to $60 
Canaccord Genuity Maintains Buy on Pulse Biosciences, Raises Price Target to $58 
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday 
This HCA Healthcare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Your note
Sign in to keep a note on PLSE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARRETT BURKE T | Former | Sale | Dec 10, 2024 | 63,172 |
| DANAHY KEVIN PATRICK | Officer | Sale | Feb 17, 2026 | 43,298 |
| DUGGAN ROBERT WILLIAM | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | May 10, 2026 | 49,291,700 |
| LAVIOLETTE PAUL A | Chief Executive Officer | Purchase | May 10, 2026 | 15,846 |
| UECKER DARRIN R | Chief Technology Officer | Sale | Sep 16, 2025 | 284,406 |
| ZANGANEH MAHKAM | Director | Conversion of Exercise of derivative security | Feb 2, 2025 | 873,469 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 2.07% | 1,466,702 | 78.16M | Jun 29, 2026 |
| Bank of America Corporation | 2.04% | 1,446,611 | 77.09M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 1.11% | 788,640 | 42.03M | Jun 29, 2026 |
| Portolan Capital Management, LLC | 1.06% | 753,333 | 40.15M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 1.06% | 748,638 | 39.89M | Jun 29, 2026 |
| Balyasny Asset Management LP | 1.01% | 718,103 | 38.27M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 0.78% | 554,612 | 29.56M | Jun 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 0.69% | 485,300 | 25.86M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 0.69% | 489,643 | 26.09M | Sep 29, 2026 |
| MFS SERIES TRUST I-MFS New Discovery Fund | 0.48% | 339,453 | 18.09M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.30% | 215,880 | 11.50M | Jun 29, 2026 |
| TR PRICE-Price (T.Rowe) New Horizons Trust | 0.30% | 214,400 | 11.43M | Jun 29, 2026 |